LVADs Trigger More Than Strokes — Registry Reveals Hidden Neurologic Dangers
A large registry study finds 8% of LVAD recipients suffer non-stroke brain events, with mortality risks rivaling or exceeding stroke outcomes.
Summary
A registry study of nearly 12,000 advanced heart failure patients fitted with the HeartMate 3 left ventricular assist device (LVAD) found that non-stroke neurologic events are just as common as strokes — each occurring in about 8% of patients over a median 1.4 years. These events, including encephalopathy, subarachnoid hemorrhage, and covert brain injury detected only on imaging, were associated with dramatically reduced survival. Two-year survival dropped to 56% for non-stroke neurologic events and 45% for strokes, compared with much better outcomes in those with no neurologic complications. Researchers identified pre-LVAD use of ECMO and surgery performed at the same time as LVAD implantation as potentially modifiable risk factors. Experts say neurologic monitoring after LVAD placement must expand well beyond stroke screening.
Detailed Summary
Left ventricular assist devices are a critical lifeline for patients with advanced heart failure, but new registry data reveal that the brain risks extend far beyond the strokes that have historically dominated clinical concern. This matters for longevity because heart failure and its treatments affect millions of aging adults, and neurologic complications directly cut survival and functional capacity.
Analyzing the U.S. INTERMACS database, researchers led by Omar Saeed, MD, of Montefiore Medical Center studied nearly 12,000 recipients of the contemporary HeartMate 3 LVAD. Over a median follow-up of 1.4 years, roughly 8% experienced a stroke and another 8% suffered a non-stroke neurologic adverse event — a category encompassing encephalopathy, subarachnoid hemorrhage, subdural hemorrhage, and covert brain injury found incidentally on imaging.
The mortality data were stark. Compared with patients who had no neurologic events, stroke raised the risk of death 7.3-fold. Overt central nervous system injury without stroke carried an even higher hazard ratio of 12.58, while covert imaging-detected brain injury reached 9.19. Even encephalopathy — often seen as a secondary or reversible condition — tripled mortality risk with an HR of 3.69. Two-year survival was 45% post-stroke and 56% after non-stroke neurologic events.
Two potentially modifiable risk factors emerged: the use of extracorporeal membrane oxygenation before LVAD implantation and surgery performed at the same time as device placement. Clinicians who can avoid or minimize these exposures may reduce neurologic burden. Experts also cautioned that encephalopathy may signal underlying systemic illness rather than being a direct cause of death, highlighting the need for comprehensive systemic evaluation alongside neurologic assessment.
The study's main caveat is its retrospective, registry-based design, which limits causal inference. Nonetheless, the findings argue strongly that neurologic outcome reporting for LVADs must standardize non-stroke events alongside strokes to give patients and clinicians a complete risk picture.
Key Findings
- Non-stroke neurologic events occur in ~8% of LVAD recipients — equal in frequency to stroke over 1.4 years.
- Overt non-stroke CNS injury carries the highest mortality hazard ratio at 12.58, exceeding even stroke (HR 7.3).
- Encephalopathy alone triples death risk (HR 3.69), signaling systemic illness as well as possible brain injury.
- Pre-LVAD ECMO use and concomitant surgery are potentially modifiable targets to lower neurologic complications.
- Two-year survival after any neurologic event is poor: 45% post-stroke, 56% after non-stroke neurologic events.
Methodology
This is a news report summarizing a peer-reviewed retrospective registry study published in JACC: Heart Failure, a high-credibility cardiology journal. The evidence base is the U.S. INTERMACS database covering nearly 12,000 HeartMate 3 LVAD recipients; the retrospective design limits causal conclusions but the large sample size strengthens the associations reported.
Study Limitations
The retrospective registry design precludes causal inference and may introduce selection and reporting biases. The article is a news summary and does not provide full methodological details, so primary source verification is recommended. Encephalopathy mortality risk may partly reflect confounding by underlying systemic conditions such as infection or multiorgan dysfunction rather than direct brain injury.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: